Label schedules

Semaglutide dose schedule

Semaglutide appears in Ozempic, Wegovy, and Rybelsus labeling, but it does not have one interchangeable schedule across those products. Route, indication, and presentation change the reference. This page compares adult injection schedules for Ozempic and Wegovy and identifies the separate tablet schedules. Milligrams remain the dose unit throughout; a syringe-unit conversion belongs to a known liquid concentration, not to the generic name alone. Ozempic labelWegovy labelRybelsus label

Updated . Last editorial review by The PinPoint team

What is the semaglutide dose schedule?

Both semaglutide injection labels start at 0.25 mg once weekly for four weeks, then 0.5 mg. Ozempic can go to 1 mg and then 2 mg, each after at least four weeks. Wegovy steps through 1 mg and 1.7 mg to a maintenance dose of 1.7 or 2.4 mg, with 7.2 mg possible for adult weight reduction.

What does the Ozempic label schedule say?

Ozempic injection starts at 0.25 mg weekly for four weeks and then reaches 0.5 mg weekly. A later increase to 1 mg requires at least four weeks at 0.5 mg when additional glycemic control is needed; an increase to 2 mg requires at least four weeks at 1 mg. The current label also specifies 1 mg after at least four weeks at 0.5 mg for its kidney-outcome indication. Ozempic label

01 02 03 04
Read phases with the table below. Bar height does not represent dose size.
Ozempic injection: section 2.2 Ozempic label
Timing (weeks)Weekly amountCondition
1–40.25 mg weeklyInitiation
5 onward0.5 mg weeklyAfter four weeks at 0.25 mg
After ≥4 weeks at 0.5 mg1 mg weeklyIf more glycemic control is needed; also the labeled kidney-outcome dose
After ≥4 weeks at 1 mg2 mg weeklyIf more glycemic control is needed; maximum weekly dose

What does the Wegovy label schedule say?

Wegovy injection uses four-week stages of 0.25, 0.5, 1, and 1.7 mg weekly before maintenance. For adult weight management, the ongoing amount is 1.7 or 2.4 mg weekly. The current label permits 7.2 mg for adults who tolerate 2.4 mg for at least four weeks when additional weight reduction is clinically indicated. That conditional option does not apply to every Wegovy indication or age group. Wegovy label

The label can also delay escalation when a stage is not tolerated. Thus, the numbered weeks summarize the reference sequence, not a promise about the calendar of an individual person. A record that remains at one strength longer than the table illustrates is not enough information to judge the prescription. The table is a way to read the label, not a substitute for it. Wegovy label

Wegovy injection: adult weight-management reference, section 2.2 Wegovy label
Timing (weeks)Weekly amountCondition
1–40.25 mg weeklyInitiation
5–80.5 mg weeklyEscalation
9–121 mg weeklyEscalation
13–161.7 mg weeklyEscalation
17 onward1.7 or 2.4 mg weeklyAdult weight-management maintenance
After ≥4 weeks at 2.4 mg7.2 mg weekly, if prescribedAdult weight reduction only: tolerability and clinical need conditions apply

Why do semaglutide tablets need a separate table?

Rybelsus uses 3 mg daily for thirty days, then 7 mg daily for the next thirty days, followed by 7 or 14 mg according to glycemic need. Ozempic tablets use different labeled strengths: 1.5, 4, and 9 mg. The combined tablet label says those two tablet products are not substitutable milligram for milligram. Copying an injection amount into either tablet schedule loses essential product information. Rybelsus label

Wegovy tablets have their own sequence of 1.5, 4, and 9 mg daily in successive thirty-day stages, followed by 25 mg daily. The injection and tablet label includes switching instructions, which are not a general arithmetic ratio between routes. The daily oral amount and the weekly injected amount describe different labeled uses, even though both names include semaglutide. Wegovy label

What is the half-life of semaglutide?

The Ozempic prescribing information gives an elimination half-life of approximately one week after subcutaneous administration. The decay table below uses that value, 168 hours (7 days); it is not a measurement of anyone's levels or of how long an effect lasts. Ozempic label

A weekly interval and this half-life have the same duration, so the elementary decay calculation leaves half of one modeled contribution after seven days. This equality is arithmetic, not evidence that an individual follows the curve. The label's value concerns the injected presentation; the number does not describe absorption of every formulation. Ozempic label

Starting at an arbitrary 100%, each elapsed half-life divides the remaining modeled amount by two. The table describes a single contribution with no further entries, and its percentages are not percentages of benefit or activity. The Ozempic label states that semaglutide will be present in the circulation for about 5 weeks after the last dose; exponential decay never reaches exactly zero, and that figure is not a detection window or a washout instruction. Ozempic label

Semaglutide: normalized amount remaining, using the label's elimination half-life of about 1 week (168 hours) Ozempic label
Half-livesHoursDaysRemaining (rounded)
000100.0%
1168750.0%
23361425.0%
35042112.5%
4672286.3%

What the label's once-weekly schedule means mathematically: in an equal-input model, the limiting peak accumulation ratio is 1 ÷ (1 − 2 raised to minus interval divided by half-life). It compares a repeated pattern with one instantaneous input and assumes the same interval continues indefinitely. Ozempic label

  • Once weekly, if evenly spaced: 168 hours between entries; 50% of one contribution remains at that marker; limiting accumulation ratio 2. Ozempic label

The Ozempic label states that steady-state exposure is achieved following 4 to 5 weeks of once-weekly administration. Changing amounts, missed entries, irregular spacing and absorption change the pattern. The calculation does not decide when to start, stop, or change anything. Ozempic label

What do the semaglutide labels say about a missed dose?

The two injection labels use different windows. Ozempic: take a missed dose "as soon as possible within 5 days after the missed dose"; after more than 5 days, skip it and take the next dose on the regularly scheduled day. Ozempic label

Wegovy counts forward instead, to the next scheduled dose. If that dose is more than 2 days away, take the missed one as soon as possible. If it is less than 2 days away, skip it and resume on the regular day of the week. If 2 or more doses in a row are missed, the label says to restart dose escalation at a lower dose. Wegovy label

Missed semaglutide injection: what each label says Ozempic labelWegovy label
LabelRule
OzempicWithin 5 days of the missed dose, take it as soon as possible; after more than 5 days, skip it
WegovyNext dose more than 2 days away: take it as soon as possible. Less than 2 days away: skip it
Wegovy, 2 or more doses missed in a rowRestart dose escalation at a lower dose

How do you log a late dose in PinPoint?

Log the dose at the time you actually took it, not the time it was planned. PinPoint lets you backfill an entry, so a late dose sits on the day it happened. That makes the 5-day and 2-day windows in the labels easy to check against the history afterwards. App features

PinPoint includes reminders, titration phases, and a color-coded calendar. Injection logs capture compound, amount, site, and pain level, with backfilling for earlier entries. A meaningful history keeps the dose associated with its actual recorded date. Daily notes and side-effect severity ratings can preserve observations without turning timing alone into a causal conclusion. App features

Useful distinctions

Questions

Is there one semaglutide dosage chart for every product?

No. The labels contain distinct injection and oral schedules, with indication-specific conditions. A useful reference identifies the brand presentation and route before displaying the amount. Ozempic labelWegovy labelRybelsus label

Can PinPoint show a changing prescribed phase?

The app description includes step-up and step-down titration phases and reminders that follow the entered schedule. It does not describe the app as selecting a clinical dose. App features

Is the half-life of Semaglutide the same for everyone?

The Ozempic label gives an elimination half-life of approximately 1 week. It states that age, sex, race, ethnicity and renal impairment have no clinically meaningful effect on semaglutide pharmacokinetics, and that exposure decreases as body weight increases. Ozempic label

What do five half-lives mean?

The Ozempic label states that, with an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose. Five half-lives of 1 week is 5 weeks. Ozempic label

What does steady state mean?

For unchanged, equally spaced inputs in a linear model, steady state means the pattern repeats from one interval to the next. About five half-lives gives roughly 97% of the limiting pattern. Peaks and troughs still occur; steady state does not mean a flat line or a recommended regimen.

Your record, together

Keep the details attached to the date.

Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.

Get PinPoint on the App Store

Sources & scope

Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.

  1. PinPoint feature description

    Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.

  2. Ozempic prescribing information

    2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: adec4fd2-6858-4c99-91d4-531f5f2a2d79, DailyMed SPL of 1 June 2026.

  3. Rybelsus prescribing information

    2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: 27f15fac-7d98-4114-a2ec-92494a91da98, DailyMed SPL of 30 January 2026.

  4. Wegovy prescribing information

    2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: ee06186f-2aa3-4990-a760-757579d8f77b, DailyMed SPL of 18 June 2026.